Cargando…

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin

Despite favorable responses to platinum-based chemotherapy in ovarian cancer (OC), chemoresistance is still a major cause of treatment failure. Hence, we develop a novel synthetic agent, COM33, to relieve the chemoresistance caused by carboplatin. The anti-cancerous effects of the combination of COM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zhiyang, Jin, Li, Shen, Jian, Shi, Weihui, Xu, Yue, Ye, Longyun, Liu, Junxi, Pan, Jiexue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157527/ https://www.ncbi.nlm.nih.gov/pubmed/36647720 http://dx.doi.org/10.3724/abbs.2022195

Ejemplares similares

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer
por: Zhang, Yiping, et al.
Publicado: (2018)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer
por: Konstantinopoulos, Panagiotis A, et al.
Publicado: (2008)

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
por: Pénzváltó, Zsófia, et al.
Publicado: (2014)

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
por: Gao, Bo, et al.
Publicado: (2018)

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance
por: Gorski, Justin W., et al.
Publicado: (2021)

Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
por: Fotopoulou, Christina
Publicado: (2014)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

Knockdown of FUSE binding protein 1 enhances the sensitivity of epithelial ovarian cancer cells to carboplatin
por: Zhang, Jinli, et al.
Publicado: (2017)

Exploration of the sequential gene changes in epithelial ovarian cancer induced by carboplatin via microarray analysis
por: Wei, Shuqing, et al.
Publicado: (2017)

Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer
por: Mikkelsen, Mette Schou, et al.
Publicado: (2020)

Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
por: Allen, Valerie A., et al.
Publicado: (2016)

Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin
por: Deng, Minjie, et al.
Publicado: (2019)

Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4
por: Zhou, Songhui, et al.
Publicado: (2020)

Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
por: Schwarzenbach, Heidi, et al.
Publicado: (2019)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy
por: Chen, Tao, et al.
Publicado: (2009)

The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2016)

Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer
por: Wenzel, Alexander T., et al.
Publicado: (2022)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models
por: Al-Eisawi, Zaynab, et al.
Publicado: (2013)

Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge
por: Pandey, Avinash, et al.
Publicado: (2014)

Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study
por: Wang, Fei, et al.
Publicado: (2016)

S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin
por: Wang, Lingzhi, et al.
Publicado: (2019)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer()
por: Yu, Jun, et al.
Publicado: (2013)

Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan
por: Harano, Kenichi, et al.
Publicado: (2014)

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
por: Teschendorff, Andrew E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9bf2f8imn3c95m68vkv95ph2p3